Skip to main content
Premium Trial:

Request an Annual Quote

Hey, It Makes You Better. Do We Really Need to Know More than That?

Omics! Omics! has a post on recent news from Millennium that "their Phase III trial for Velcade in newly diagnosed multiple myleoma had halted early because the experimental arm was performing so much better than the control arm," writes Keith Robison, who used to work at Millennium. He goes on to talk about the "therapeutic ignorance" at companies involved in drug discovery and development; the biology of what's really going on is often not fully understood even when drugs are on the market. Robison asks, "Will we ever move from incremental, conservative, empirical approaches to some rational, mechanistic hypothesis-driven approach?" In his view, he's hopeful that it will eventually happen, but says that in the near term it remains highly unlikely.


The Scan

Tens of Millions Saved

The Associated Press writes that vaccines against COVID-19 saved an estimated 20 million lives in their first year.

Supersized Bacterium

NPR reports that researchers have found and characterized a bacterium that is visible to the naked eye.

Also Subvariants

Moderna says its bivalent SARS-CoV-2 vaccine leads to a strong immune response against Omicron subvariants, the Wall Street Journal reports.

Science Papers Present Gene-Edited Mouse Models of Liver Cancer, Hürthle Cell Carcinoma Analysis

In Science this week: a collection of mouse models of primary liver cancer, and more.